Search
SAGE-718
Indications:
- experimental agent for treatment of Alzheimer's disease, Huntington's disease & Parkinson's disease
Mechanism of action:
- positive modulator of NMDA receptors
Clinical trials:
- within 2 weeks, improvements in executvie function, learning & memory in patients with Alzheimer's disease
- within 4 weeks, improvement in Montreal Cognitive Assessment scores (+2.3)
General
neurologic agent
References
- Whitlock Burton K
Experimental Drug May Boost Executive Function in Alzheimer's
Medscape. March 31, 2022
https://www.medscape.com/viewarticle/971365